Analysts forecast that VBI Vaccines Inc (NASDAQ:VBIV) will announce $970,000.00 in sales for the current quarter, according to Zacks. Two analysts have issued estimates for VBI Vaccines’ earnings, with estimates ranging from $940,000.00 to $1.00 million. VBI Vaccines reported sales of $2.68 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 63.8%. The company is scheduled to report its next earnings report on Monday, February 24th.
On average, analysts expect that VBI Vaccines will report full year sales of $2.60 million for the current financial year, with estimates ranging from $2.59 million to $2.60 million. For the next year, analysts expect that the business will post sales of $16.78 million, with estimates ranging from $5.25 million to $28.30 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for VBI Vaccines.
VBI Vaccines (NASDAQ:VBIV) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.15) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by ($0.02). VBI Vaccines had a negative net margin of 1,458.97% and a negative return on equity of 70.54%. The business had revenue of $0.65 million during the quarter, compared to analysts’ expectations of $0.90 million.
In other news, major shareholder Perceptive Advisors Llc bought 20,000,000 shares of the firm’s stock in a transaction that occurred on Monday, September 23rd. The shares were bought at an average cost of $0.50 per share, for a total transaction of $10,000,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Jeff Baxter bought 150,000 shares of the firm’s stock in a transaction that occurred on Monday, September 30th. The stock was purchased at an average price of $0.50 per share, for a total transaction of $75,000.00. Following the completion of the transaction, the chief executive officer now directly owns 608,255 shares of the company’s stock, valued at approximately $304,127.50. The disclosure for this purchase can be found here. Insiders purchased 30,212,000 shares of company stock worth $15,105,440 over the last quarter. 10.50% of the stock is owned by company insiders.
Several large investors have recently bought and sold shares of VBIV. General American Investors Co. Inc. lifted its position in shares of VBI Vaccines by 23.2% in the second quarter. General American Investors Co. Inc. now owns 2,174,264 shares of the biopharmaceutical company’s stock worth $2,544,000 after buying an additional 409,800 shares in the last quarter. JPMorgan Chase & Co. purchased a new stake in VBI Vaccines during the second quarter valued at approximately $25,000. Bank of Montreal Can raised its position in VBI Vaccines by 71.8% during the second quarter. Bank of Montreal Can now owns 37,604 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 15,717 shares during the period. Charles Schwab Investment Management Inc. raised its position in VBI Vaccines by 664.5% during the second quarter. Charles Schwab Investment Management Inc. now owns 200,848 shares of the biopharmaceutical company’s stock valued at $235,000 after purchasing an additional 174,576 shares during the period. Finally, Fosun International Ltd raised its position in VBI Vaccines by 43.6% during the second quarter. Fosun International Ltd now owns 1,051,126 shares of the biopharmaceutical company’s stock valued at $1,156,000 after purchasing an additional 319,045 shares during the period. Institutional investors own 40.91% of the company’s stock.
Shares of VBI Vaccines stock traded down $0.04 during trading hours on Friday, hitting $0.82. The company’s stock had a trading volume of 3,461,023 shares, compared to its average volume of 1,686,317. The business has a 50 day moving average price of $0.63 and a two-hundred day moving average price of $0.88. VBI Vaccines has a 12-month low of $0.47 and a 12-month high of $2.20. The company has a market cap of $160.13 million, a PE ratio of -0.85 and a beta of 0.79. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.84 and a current ratio of 1.88.
VBI Vaccines Company Profile
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.